Price
$6.27
Increased by +2.62%
Dollar volume (20D)
1.59 M
ADR%
5.99
Earnings report date
Aug 5, 2024
Shares float
33.79 M
Shares short
1.82 M [5.38%]
Shares outstanding
43.70 M
Market cap
267.04 M
Beta
1.06
Price/earnings
N/A
20D range
5.55 7.08
50D range
5.55 8.25
200D range
3.45 10.83

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide.

The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.

Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin.

The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons.

AxoGen, Inc. is headquartered in Alachua, Florida.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
May 2, 24 -0.06
Increased by +40.00%
-0.07
Increased by +14.29%
Mar 5, 24 -0.06
Decreased by -100.00%
-0.10
Increased by +40.00%
Nov 7, 23 0.01
Increased by +200.00%
-0.06
Increased by +116.67%
Aug 7, 23 -0.03
Increased by +50.00%
-0.13
Increased by +76.92%
May 9, 23 -0.10
Increased by +50.00%
-0.14
Increased by +28.57%
Mar 14, 23 -0.03
Increased by +62.50%
-0.11
Increased by +72.73%
Nov 8, 22 -0.01
Increased by +88.89%
-0.12
Increased by +91.67%
Aug 3, 22 -0.06
Increased by +33.33%
-0.14
Increased by +57.14%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 24 41.38 M
Increased by +12.86%
-6.63 M
Increased by +1.12%
Decreased by -16.04%
Increased by +12.38%
Dec 31, 23 42.92 M
Increased by +18.69%
-3.89 M
Increased by +24.10%
Decreased by -9.07%
Increased by +36.05%
Sep 30, 23 41.27 M
Increased by +11.67%
-4.09 M
Decreased by -11.63%
Decreased by -9.91%
Increased by +0.03%
Jun 30, 23 38.16 M
Increased by +10.74%
-6.66 M
Increased by +8.44%
Decreased by -17.46%
Increased by +17.32%
Mar 31, 23 36.66 M
Increased by +18.24%
-6.71 M
Increased by +40.46%
Decreased by -18.30%
Increased by +49.64%
Dec 31, 22 36.16 M
Increased by +14.67%
-5.13 M
Increased by +2.97%
Decreased by -14.18%
Increased by +15.38%
Sep 30, 22 36.96 M
Increased by +18.44%
-3.66 M
Increased by +48.70%
Decreased by -9.91%
Increased by +56.69%
Jun 30, 22 34.45 M
Increased by +2.60%
-7.27 M
Increased by +7.90%
Decreased by -21.11%
Increased by +10.24%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY